Key statistics
On Friday, Takeda Pharmaceutical Co Ltd (4502:TYO) closed at 4,113.00, 6.78% above its 52-week low of 3,852.00, set on Aug 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4,124.00 |
---|---|
High | 4,137.00 |
Low | 4,109.00 |
Bid | 4,112.00 |
Offer | 4,127.00 |
Previous close | 4,121.00 |
Average volume | 3.53m |
---|---|
Shares outstanding | 1.59bn |
Free float | 1.59bn |
P/E (TTM) | 22.66 |
Market cap | 6.56tn JPY |
EPS (TTM) | 181.90 JPY |
Annual div (ADY) | 192.00 JPY |
---|---|
Annual div yield (ADY) | 4.66% |
Div ex-date | Sep 27 2024 |
Div pay-date | Dec 02 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
- Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
- Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
- Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
- Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
More ▼